Raxibacumab (ABthrax), a human IgG1 monoclonal antibody, targets the protective antigen (PA) of Bacillus anthracis. It inhibits the toxic impact of anthrax by obstructing the PA's attachment to host cell receptors, preventing the subsequent harmful effects. This compound is utilized in anti-anthrax research [1] [2].

拉西巴库单抗（Raxibacumab，150 μg/kg或300 μg/kg，静脉注射，单次给药）在炭疽杆菌致死性毒素（LeTx）首次暴露后6小时内使用，能够显著提高大鼠的存活率[3]。